Gene Literature Dashboard

Viewing December 1985 — 3 paper(s) from the local store. (Local view only — run without --view to fetch new papers.)
← November 1985 January 1986 →
Also flagged:AT-IIIovalbuminalpha 1-antitrypsinangiotensinogen
Journal Article 1985-12-01 ✓ 2 Snippets Jagd S, Vibe-Pedersen K, Magnusson S.
In-Text Gene Mentions

…introns in theantithrombin-IIIgene.…

…introns in theantithrombin-III(AT-III) gene are…

Show Full Abstract

At least two of the introns in the antithrombin-III (AT-III) gene are located in positions different from those of the other three proteins in this superfamily for which the gene structures are known, namely, ovalbumin, alpha 1-antitrypsin and angiotensinogen. In another part of the 3'-portion of the AT-III gene there is no intron where each of the other three gene structures has one.

Also flagged:Castanospermineglucosidase Iglycoproteinsecretionhepatomaalkaloid
Journal Article 1985-12-01 ✓ 1 Snippet Sasak VW, Ordovas JM, Elbein AD, Berninger RW.
In-Text Gene Mentions

…extent, that ofantithrombin-III.…

Show Full Abstract

We studied the effect of the plant alkaloid castanospermine on the biosynthesis and secretion of human hepatoma glycoproteins. The HepG-2 cells, grown in the presence or absence of the alkaloid, were labelled with [2-3H]mannose and then the labelled glycopeptides were prepared by Pronase digestion. This material was analysed by gel filtration on Bio-Gel P-4 before and after treatment with endo-beta-N-acetylglucosaminidase H. Castanospermine caused an accumulation of high-mannose oligosaccharides, by 70-75% over control. The major accumulated product, which could also be labelled with [3H]galactose and was only partially susceptible to alpha-mannosidase digestion, was identified by h.p.l.c. as a Glc3Man9GlcNAc. Thus the alkaloid inhibits glucosidase I in the human hepatoma cells. Analysis of total glycoproteins secreted by the cells into the medium revealed the presence of only complex oligosaccharides in both control and treated cultures, and the amount of the oligosaccharides labelled with radioactive mannose, galactose or N-acetylmannosamine, secreted by treated cells, was decreased by about 60%. The rate of secretion of total protein labelled with [35S]methionine and precipitated from the medium with trichloroacetic acid was inhibited by up to 40% in the presence of castanospermine. Pulse-chase studies utilizing [35S]methionine labelling were performed to study the effect of the alkaloid on secretion of individual plasma proteins. Immunoprecipitation at different chase times with monospecific antisera showed that castanospermine markedly decreased the secretion rates of alpha 1-antitrypsin, caeruloplasmin and, to a lesser extent, that of antithrombin-III. Secretions of apolipoprotein E, a glycoprotein containing only O-linked oligosaccharide(s), and albumin, a non-glycosylated protein, were not affected by the drug. It is suggested that castanospermine inhibits secretion of at least some glycoproteins containing N-linked oligosaccharides, owing to the inhibition of oligosaccharide processing.

Also flagged:-III deficiencyvenous thromboembolismvenous thrombosispulmonary embolismhereditaryantithrombin-III deficiency
Journal Article 1985-12-01 ✓ 5 Snippets Vikydal R, Korninger C, Kyrle PA, Niessner H, Pabinger I, Thaler E, Lechner K.
In-Text Gene Mentions

Antithrombin-III activity was determined in 752 patients with a history of venous thrombosis and/or pulmonary embolism.

Antithrombin-IIIactivity was determined…

…(7.18%) had anantithrombin-IIIactivity below the…

…slight deficiency) hereditaryantithrombin-IIIdeficiency was unlikely.…

…prevalence of hereditaryantithrombin-IIIdeficiency was higher…

Show Full Abstract

Antithrombin-III activity was determined in 752 patients with a history of venous thrombosis and/or pulmonary embolism. 54 patients (7.18%) had an antithrombin-III activity below the normal range. Among these were 13 patients (1.73%) with proven hereditary deficiency. 14 patients were judged to have probable hereditary antithrombin-III deficiency, because they had a positive family history, but antithrombin-III deficiency could not be verified in other members of the family. In the 27 remaining patients (most of them with only slight deficiency) hereditary antithrombin-III deficiency was unlikely. The prevalence of hereditary antithrombin-III deficiency was higher in patients with recurrent venous thrombosis.